Published in Vaccine Weekly, September 13th, 2006
Study 1: Investigators have constructed and purified an HIV-TAT-survivin (T34A) mutant.
Scientists in China report, "As a novel member of the IAP family, survivin was observed to express in the most common human cancers. Anticancer therapy targeting survivin has drawn considerable attention. This report presented firstly construction of recombinant plasmid pRSET-B-TAT-survivin (T34A), expression in Escherichia coli, purification, renaturation, and bioactivity. The cDNA encoding survivin was cloned by RTPCR from breast cancer cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.